CN Patent

CN112961104A — 用于治疗nk-1受体相关疾病的取代的4-苯基吡啶

Assigned to Helsinn Healthcare SA · Expires 2021-06-15 · 5y expired

What this patent protects

本申请涉及用于治疗NK‑1受体相关疾病的取代的4‑苯基吡啶，公开了用于预防和/或治疗由神经激肽(NK 1 )受体病理生理学介导的疾病的化合物、组合物和方法。所述化合物具有通式(I)：

USPTO Abstract

本申请涉及用于治疗NK‑1受体相关疾病的取代的4‑苯基吡啶，公开了用于预防和/或治疗由神经激肽(NK 1 )受体病理生理学介导的疾病的化合物、组合物和方法。所述化合物具有通式(I)：

Drugs covered by this patent

fosnetupitant-chloride-hydrochloride (FOSNETUPITANT CHLORIDE HYDROCHLORIDE)

Patent Metadata

Patent number: CN112961104A
Jurisdiction: CN
Classification: —
Expires: 2021-06-15
Drug substance claim: No
Drug product claim: No
Assignee: Helsinn Healthcare SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.